Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 May;26(5):980-990.
doi: 10.1002/ejp.1941. Epub 2022 Mar 23.

Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: A systematic review of randomized controlled trials and meta-analysis

Vincent Hary  1   2 , Sebastien Schitter  2   3 , Valeria Martinez  2   3   4   5
Affiliations
Meta-Analysis

Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: A systematic review of randomized controlled trials and meta-analysis

Vincent Hary et al. Eur J Pain. 2022 May.

Abstract

Background and objective: Botulinum toxin type A (BTX-A) is a recently developed treatment for the management of peripheral neuropathic pain. The objective of this study was to provide a synthesis of the evidence concerning the efficacy and safety of subcutaneous botulinum toxin type A injections.

Databases and data treatment: We searched the MEDLINE, EMBASE, LILACS, Cochrane, and Clinical Trial Register databases for randomized controlled trials comparing subcutaneous BTX-A to placebo injections for treating chronic peripheral neuropathic pain. The primary endpoint was the assessment of pain 1 month after the injection. The secondary outcomes were the assessment of pain at 3 months, neuropathic pain intensity and quality of life at 1 and 3 months, and adverse effects. A random-effect meta-analysis was performed on the combined data. Evidence quality was rated by the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) method.

Results: Ten randomized controlled trials including 505 patients were included in this review (registration number CRD42021239108). At 1 and 3 months after injection, the BTX-A groups had a lower mean difference (MD) in pain score (MD -1.87 (confidence intervals [CIs] -2.91; -0.83) and -1.38 (CI -1.95; -0.81), respectively). Subgroup analysis showed greater efficacy for diabetic polyneuropathy (MD -2.48, [-3.22; -1.74]). We found no impact of BTX-A on quality of life and no difference in adverse effect between BTX-A and placebo. The evidence was considered of moderate quality.

Conclusion: The pooled data suggest that subcutaneous BTX-A injections have a clinically significant effect, decreasing pain for three months after the injection, but no benefit in terms of quality of life has yet been demonstrated.

Significance: We found that botulinum toxin is efficient and safe for the treatment of neuropathic pain, especially for diabetic polyneuropathy. Botulinum toxin type A, used for years in neurology, rehabilitation and physical medicine, has proved innocuous and effective, and should be considered as a serious alternative for pain treatment.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. The Cochrane Collaboration. (2020). Review Manager (RevMan) [Computer program].
    1. Apalla, Z., Sotiriou, E., Lallas, A., Lazaridou, E., & Ioannides, D. (2013). Botulinum toxin A in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clinical Journal of Pain, 29, 857-864. https://doi.org/10.1097/AJP.0b013e31827a72d2
    1. Attal, N., de Andrade, D. C., Adam, F., Ranoux, D., Teixeira, M. J., Galhardoni, R., Raicher, I., Üçeyler, N., Sommer, C., & Bouhassira, D. (2016). Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): A randomised, double-blind, placebo-controlled trial. The Lancet Neurology, 15, 555-565. https://doi.org/10.1016/S1474-4422(16)00017-X
    1. Attal, N., Lanteri-Minet, M., Laurent, B., Fermanian, J., & Bouhassira, D. (2011). The specific disease burden of neuropathic pain: Results of a French nationwide survey. Pain, 152, 2836-2843. https://doi.org/10.1016/j.pain.2011.09.014
    1. Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., Norris, S., & Guyatt, G. H. (2011). GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology, 64, 401-406. https://doi.org/10.1016/j.jclinepi.2010.07.015

MeSH terms

Substances

LinkOut - more resources